|Bid||103.13 x 1400|
|Ask||103.14 x 1000|
|Day's Range||102.09 - 103.22|
|52 Week Range||83.18 - 110.33|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-5.17%|
|Beta (5Y Monthly)||0.40|
|Expense Ratio (net)||0.40%|
Speculation surrounding the novel coronavirus has taken over the stock market. Hope for a cure or, better yet, a vaccine, is driving traders into frenzies. Much of the action is centered around Moderna (NASDAQ:MRNA) and MRNA stock.Source: Shutterstock While the company had just $8.3 million in revenue for the March quarter, it entered trade May 29 with a market cap of $20.6 billion.MRNA stock has been on fire for months. In February, the shares cost $18. It was the release of Phase 1 data earlier this month that sent traders into a frenzy. That showed, as expected, that antibodies against the virus were produced in test subjects. The company also said it was rapidly scaling up production.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTraders who had been buying Moderna rumors sold the news. The shares have since fallen from the mid-80's to the mid-50's. Why Moderna?Nothing has gone wrong, from a scientific standpoint. It's just that there are no guarantees Moderna has the winning lottery ticket.There are now 28 different vaccines being researched around the world, with eight in some type of clinical trial. There are vaccines being tested in England, in China and in Australia. Two other publicly traded U.S. companies, Pfizer (NYSE:PFE) and Inovio Pharmaceuticals (NASDAQ:INO), have Covid-19 vaccine candidates in trial. Novavax (NASDAQ:NVAX), Johnson & Johnson (NYSE:JNJ), and Altimmune (NASDAQ:ALT) are all doing pre-clinical work. So are Merck (NYSE:MRK), GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY). * 7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure Moderna just got there first, with the most publicity. It announced funding on Jan. 23. It's working with the National Institute of Allergy and Infectious Diseases (NIAID), headed by the now-famous Dr. Anthony Fauci. It won an invitation to the White House to talk about its candidate, mRNA-1273. Why Not Moderna?The problem is that vaccines are hard. It's not enough to create antibodies against the disease. A vaccine must stop the spread safely across millions or (in this case) billions of doses.Safety is one issue. Four of the 45 people tested in the Phase 1 study developed reactions to the Moderna vaccine. One 29-year old tweeted that he got a 103 degree fever. He said his dose was 10 times what other patients got, and he didn't go to a hospital in fear of triggering "anti-vax" people.Efficacy is a second issue. Only eight of the subjects produced binding antibodies. Only four were sampled for neutralizing antibodies. The level of T-Cell generation, a measure of how the body is attacking the virus, wasn't mentioned.Moderna's own actions are also an issue. The company announced a $1 billion secondary offering right after its Phase 1 results came out. Some executives sold shares within days. Moderna is moving directly into a Phase 3 study, and mass production, while its Phase 1 is still being evaluated.All these actions have raised suspicions among people who know both science and market valuations. The Bottom Line on MRNA StockThis is my fourth piece on Moderna in six months.I was very positive about MRNA stock when it came public in December. Its methodology, using Messenger RNA, impressed me. In April, I called Moderna "the greatest coronavirus speculation." The problem is success against Covid-19 is now built-into the stock price. Success is far from guaranteed. There are many other horses in this race. It's far from clear how profitable this vaccine will be.It's possible mRNA-1273 could be the start of a business that goes on for decades. It's possible that mRNA-1273 proves Moderna's methodology and it becomes one of the world's great companies. It's also possible that mRNA-1273 fails in Phase 3.There are too many known unknowns for me to recommend investing in MRNA stock at its present price. But you're welcome to speculate.Dana Blankenhorn has been a financial journalist since 1978. His latest book is Technology's Big Bang: Yesterday, Today and Tomorrow with Moore's Law, essays on technology available at the Amazon Kindle store. Follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in JNJ. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * The Huge Story for 2020 & Beyond That You Aren't Hearing About * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * The 1 Stock All Retirees Must Own The post Why Moderna Stock Is Still Only Good for Speculators appeared first on InvestorPlace.
Treasury yields have been stuck near all-time lows ahead of the Fed’s new Main Street Lending Program that is supposed to roll out by the end of this week. Guy Benstead, portfolio manager at Shelton Capital Management joins Yahoo Finance's Brian Sozzi and Alexis Christoforous to discuss.
Investors trying to front-run the Federal Reserve’s purchase of below-investment grade bond ETFs are further concentrating the market for these funds.
On Tuesday, the Federal Reserve kicked off its purchases of corporate bond exchange-traded funds. The Secondary Market Corporate Credit Facility will be managed by BlackRock. Yahoo Finance’s Brian Cheung breaks down what the historic move means for the central bank on The Final Round.
Days after Apple Inc. (AAPL) said it could not provide guidance for the next quarter, the company raised $8.5 billion through cheap bonds with maturities ranging from three years to 30 years. It will use this money to fund share buybacks and for other general corporate purposes.
Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to be in a downtrend based on the fact that its 50-day moving average is below its 200-day moving average, which are popular indicators for gauging long-term and medium-term trends, respectively. Second, each of these ETFs is also trading above its 20-day moving average, thereby offering a near-term “sell on the pop” opportunity given the longer-term downtrend at hand. Note that this prospect list also features a liquidity screen by excluding ETFs with average trading volumes below the one million shares mark. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
The ETF industry continues to attractive billions of dollars in new investor money, and many have turned to fixed-income ETFs this year.
High-yield, junk bonds and related ETFs have grown in popularity in a lower-for-longer rate environment, but the speculative-grade fixed-income market may be flashing early warning signals. Year-to-date, ...
One factor that I believe is propping up equities is ultra-low interest rates, combined with massively high bond prices (remember that bond prices and yields move inversely). explains Matt Kerkhoff, money manager and editor of Sigma Point Capital's Market Analysis.
As some grow wary of risks in the equity market, investors are shifting their attention to corporate bonds and related exchange traded funds. According to Lipper data, investors yanked $46.2 billion from ...
Investment company Park Avenue Institutional Advisers LLC (Current Portfolio) buys SPDR Barclays High Yield Bond ETF, iShares iBoxx $ High Yield Corporate Bond ETF during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Park Avenue Institutional Advisers LLC. Continue reading...
While the Federal Reserve eyes interest rate cuts to prop up the economy, fixed-income investors are looking into speculative-grade, junk bond ETFs for the lower-for-longer yield environment. Among the ...
With more expecting the Federal Reserve to cut interest rates ahead, exchange traded funds that track long-term debt are beginning to pick up steam as investors hunt for attractive income in a lower-for-longer yield environment. Investors and analysts highlighted the worsening projections for growth as a catalyst for the Federal Reserve to its loosening monetary policy outlook instead of tightening it. Sentiment for a rate cut picked up Wednesday and Thursday after the Fed held rates steady but signaled a possible cut in the months ahead to combat the weakening effects of a prolonged trade war.
ETFs have increasingly grown in popularity as many investors utilize the nifty too to quickly weave in and out volatile market conditions. In a recent research note, Deutsche Bank highlighted the huge ...